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ABSTRACT 
5-HT receptors are implicated in many gastrointestinal disorders. However, 
the precise role of 5-HT in mediating GI responses in Suncus murnius is still unclear. 
Therefore in this study, the effects of 5-HT and its agonists were investigated in 
Suncus. The involvement of 5-HT2C receptors in mediating emesis was also 
investigated. The ability of 5-HT and its agonists/antagonists at 5-HT1A and 5-HT2  to 
modify GI motility was investigated in vitro and in vivo.  
WAY100635 (a 5-HT1A antagonist) inhibited the contraction response to 5-HT 
in the proximal segments without affecting the maximum response; whilst enhancing 
the contraction to 5-HT (>30.0 nM) in the distal intestine. The selective 5-HT2A and 5-
HT2B receptor antagonists MDL-100907  and  RS-127445  attenuated 5-HT-induced 
contractions (<10.0 µM) in the distal segments. RS-127445 also attenuated 5-HT-
induced contractions in the central segments. The selective 5-HT2C receptor antagonist 
SB-242084,   attenuated the responses to 5-HT (> 3.0 nM) in the proximal and central 
but not the distal regions. 8-OH-DPAT-induced relaxation  was  resistant to the 
antagonism by 5-HT1A/7 antagonists. DOI in the presence of 5-HT1A/2A/2B/2C 
antagonists induced greater contraction responses (>1.0 µM) in most tissues, whilst 
RS-127445, or SB-242084, reduced the responses to DOI (< 1.0 µM) in some tissues. 
SB-242084 also suppressed emesis-induced by motion and intragastric CuSO4 .  
In conclusion, within different regions of intestine, 5-HT2 receptors are 
differently involved in contraction and emetic responses and that  8-OH-DPAT 
induces relaxation  via  non-5-HT1A/7  receptors.  Suncus could provide a model to 
investigate these diverse actions of 5-HT. 
Keywords:    5-Hydroxytryptamine; 8-OH-DPAT; DOI; 5-HT1A and 5-HT2 receptor 
subtypes; Suncus murinus intestine  
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1. Introduction 
The diversity of the actions of serotonin (5-HT) is revealed by its involvement in 
behavioural, endocrine, temperature, sleep, and gastrointestinal functions (Aghajanian, 
1995; Cowen et al., 1991; Dubovsky, 1994; Glennon and Dukat, 1995; Jacob and 
Fornal, 1995; Keppel and Sambunaris, 1995; Sandler et al., 1991; Shih et al., 1995; 
Javid and Naylor, 2002, 1999a, 1999b).   
Approximately 95% of mammalian 5-HT is produced in the gastrointestinal tract. 
Within the gut, the net effect of 5-HT in a given smooth muscle preparation will 
involve a summation of its potential excitatory and inhibitory actions (Fozard, 1985; 
Mir et al., 1988). Previous studies in the guinea pig and rat have shown the 
involvement of 5-HT receptors in mediating relaxation (5-HT4 and 5-HT7 receptors), 
contraction (5-HT2 and 5-HT3 receptors), and secretion (5-HT3 and 5-HT4 receptors) to 
the application of  exogenous serotonin (Hoyer et al., 2002). Whether or not these 
receptors are responsive to  endogenously released 5-HT is uncertain; but it is likely 
that 5-HT, through 5-HT1A, 5-HT2, 5-HT3, 5-HT4 and 5-HT7 receptors, plays a key 
role in gastrointestinal  motility patterns (Dhasmana et al., 1993; Buchheit et al., 1985; 
Chahal, 1983; Fozard, 1985, 1990; Sanger, 1987; Butler et al., 1990; Bradley et al., 
1986). Agonists and antagonists for various 5-HT receptors have been used to treat 
gastrointestinal disorders, including IBD, functional dyspepsia, and chronic 
constipation. For example, 5-HT1 receptor agonists and antagonists have been 
developed for functional dyspepsia and IBS diarrihoea-predominant (IBS-D) and 
gastroesophageal reflux disease (GERD), and 5-HT2 receptor antagnonists for IBS-D 
(Gershon and Tack, 2007;  Beattie and Smith, 2008). There is evidence that diarrhoea-
predominant IBS is associated with an elevated level of 5-HT, whereas constipation-
predominant IBS is associated with reduction in 5-HT in the colon mucosa (Spiller, 
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2008; Camilleri, 2009). Alterations in gut motility are paramount to this disorder and 
contribute to prevalence of both diarrhoea and constipation.   
There are several studies, both in humans and in experimental models, that report 
associations of symptoms of IBS and 5-HT levels in mucosal biopsies (Coates et al., 
2004; Miwa et al., 2001). Changes in the 5-HT content are also associated with IBD, 
both in Crohn’s disease and Ulcerative colitis (Wheatcroft et al., 2005; Belai et al., 
1997). Approximately 50% of patients with IBD in long-term remission have IBS-like 
symptoms related to changes in 5-HT signaling in the gut (Fernandez-Banares et al., 
2007). Moreover, 5-HT content  is increased in an experimental model of colitis 
(Oshima et al., 1999; Linden et al., 2003). Therefore, extensive research has indicated 
a privitol role for 5-HT and its receptors in many GI pathophysiological conditions 
with symptoms of a disturbed pattern of motility and emesis (Spiller, 2008; Camilleri 
et al., 2009; Gershon, 1991, Saha, 2014; Noddin et al., 2005; Crowell, 2004).  
Linking emesis to disturbed patterns of motility in rodents and guinea pigs is not 
possible; such species do not possess the emetic reflex (Horn et al., 2013). However, 
advances in emesis research have revealed the value of the House Musk Shrew, 
Suncus murinus (Ito et al., 1995; Javid and Naylor, 2002). The animal shares  several 
similarities with humans in its morphological, physiological, and genetic features 
(Hoyle et al., 2003; Ishiguro et al., 1989; Kimura et al., 1996 ) and is considered as an 
available model for the study of human physiology and pathology (Takata et al., 1999; 
Javid and Naylor, 1999a, 1999b, 2001, 2002, 2006, 2013; Cluny et al., 2008), 
particularly in field of gastroinestinal motility (Sanger et al, 2011).  
Understanding the precise role of 5-HT and its related receptors in intestinal 
pathology would ultimately lead to imporoved therapeutic strategies in a variety of GI 
disorders. Therefore, the aim of the present study is to achieve  further understanding 
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of the role of serotonin receptors in the intestine of Suncus murinus which play 
important roles in the mediation of  disturbed patterns of gastrointestinal motility in 
many pathophysiological conditions. We have previously reported that 5-HT2 and 5-
HT3 receptors play an important role in mediating a response to exogenously applied 
5-HT and its related agonists in the gastrointestinal segments of Suncus murinus 
(Javid and Naylor, 1999a, 1999b). However, the role of 5-HT2 receptor subtypes and 
other 5-HT receptors have not been investigated.  Thus the present study was 
designed to further evaluate the action of 5-HT, 8-OH-DPAT and DOI using selective  
antagonists for 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6 and 5-HT7 receptors in 
different regions of the Suncus murinus  intestine. Further in vivo experiments were 
also designed to investigate the role of 5-HT2C receptors in emesis-induced by motion 
and intragastric CuSO4. 
 
2. Materials and Methods 
 
2.1.Animals and housing conditions 
Adult House Musk shrews (Suncus murinus) of either sex from the Bradford 
University strain were used; animals used for the vomiting experiments were not re-
used for the in vitro experiments.  The shrews were individually housed and allowed 
food (AQUATIC 3, trout pellets) and water ad libitum.  Animals were also fed with 
mealworms or cat food three times per week.  The floor of the cages were covered 
with sawdust and cleaned twice a week.  The animal room was maintained at 
humidity between 45 to 55% at 19-21C. All in vitro experimental procedures were in 
compliance with the UK Animals (Scientific Procedures) Act 1986, and were carried 
out using age-matched animals adult male (72.1+1.6g).  Emesis testing was conducted 
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at the University of Pittsburgh. In Pittsburgh, adult male animals (83.1 ± 2.1 g, mean 
± SEM) were housed individually in clear plastic cages (28 × 17 × 12 cm; length x 
width x height), with a filtered air supply, under a 12:12 h light:dark cycle (lights on 
at 0700 h), in a temperature (~ 23 °C) and humidity (~ 40%) controlled environment. 
Food consisted of a mixture of 75% Purina Cat Chow Complete Formula and 25% 
Complete Gro-Fur mink food pellets. Food and drinking water were freely available.  
All experiments were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee. Animals were housed in an animal care facility 
accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care. 
 
2.2. Preparation of isolated tissues 
Animals were killed by cervical dislocation following a blow to the head. The 
whole intestine was removed and immediately placed in freshly prepared Krebs’ 
solution (composition mM: NaCl 118, KCl 4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2 2.5, 
NaHCO3 25 and glucose 10) and gassed with 95% O2 and 5% CO2 at room 
temperature. The mesentery and fatty tissue were removed and the intestine was 
emptied of its contents by flushing Krebs’ solution gently through the intestine using 
a narrow tipped pipette. The length of the intestine was approximately 10-15 cm. The 
intestine of the Suncus murinus lacks a caecum and it is difficult to distinguish 
between a duodenum, jejunum, ileum and colon. In order to create a reproducible 
dissection of specified segments, Two intact segments (each segment was 1.0 cm in 
length) were taken from 3 different regions of the intestine: the ‘proximal’ region, 1.0 
cm distal to the pyloric sphincter, the ‘central’ region of the intestine, approximately 
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5.0-7.0 cm from the pyloric sphincter, and the ‘terminal’ section of the intestine, 2.0 
cm proximal to the anal region respectively. 
The whole intact segments were bathed in 10.0 ml water-jacketed organ baths and 
placed longitudinally under 0.5 g tension (basal or resting tension, ‘g’ is the unit of 
change in tension). The Krebs’ solution was maintained at a temperature of  
37.00.5C and gassed continuously with a mixture of 95% O2 and 5% CO2 . Each 
tissue was left to equilibrate in the presence or absence of antagonist for 1 h, and 
washed every 20 min. The resting tension was re-adjusted to 0.5 g when required 
throughout the experiment. Responses were recorded using  isometric Grass 
transducers  which were connected to an Apple Macintosh Computer Performa 630 
using MacLab Software 3.5v.  
 
2.3.Experimental design: In vitro small intestine 
Using a paired experimental design, the effects of 5-HT agonists in the absence 
(control) or presence of antagonists were investigated. Preliminary experiments 
revealed that paired tissues, 2 adjacent segments taken from each intestinal region 
(one control tissue and one test tissue), showed the same response, and, therefore, all 
three regions of the intestine were selected.  
Non-cumulative dose-response curves to 5-HT (1.0 nM-30.0 M), DOI (3.0 nM-
10.0 M)   in the absence (control) or presence of antagonists were constructed. This 
method includes the single addition of each dose of drugs with a  contact time 
between tissue and each agonist of 1 min duration which was followed by two 
washings with 1 min between each wash. Each single dose of 5-HT was added at 22 
min intervals between doses. Preliminary experiments showed that the interval was 
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sufficient to avoid either tachyphylaxis or enhancement of the response to a 
subsequent challenge. The addition of agonist did not exceed 0.3% of bath volume.  
Tissues were left to equilibrate with the antagonists WAY-100635 (a 5-HT1A 
receptor antagonist, 1.0 M) (Fletcher et al., 1996), MDL-100907 (a 5-HT2A receptor 
antagonist, 1.0 M) (Ullrich and Rice, 2000), RS-127445 (a 5-HT2B receptor 
antagonist, 1.0 M) (Bonhaus et al., 1999), SB-242084 (a 5-HT2C receptor antagonist, 
1.0 M) (Kennett et al., 1997), SB258585 (a 5-HT6 receptor antagonist, 1.0 M) [33] 
or SB269970A (a 5-HT7 receptor antagonist, 1.0 M) (Hagan et al., 2000) for 1.0 
hour before the application of agonist. The antagonists were constantly present in the 
organ bath during the construction of the dose-response curves. Also, the effects of 8-
OH-DPAT (3.0, 10.0 and 30.0 M) in the absence and presence of WAY-100635 or 
SB269970A (a 5-HT7 receptor antagonist, 1.0 M) were studied. 
A control contraction to KCl (0.12 M) was also established in each tissue at the 
end of the experiments. The effect of agonists in the absence or presence of 
antagonists were also compared as a percentage of the maximum contractions 
obtained with KCl (0.12 M). Initial analysis using an internal standard (KCl) revealed 
that expression of the contractions as a percentage of the KCl control made no 
discernible difference to the results obtained and comparisons made to the absolute 
values. None of the 5-HT receptor antagonists showed any effect on the spontaneous 
activity of the tissues examined. In separate experiments the integrity of the 
preparation were evaluated for the duration of the experiments. In such experiments 
KCl induced reproducible contraction responses for the whole duration of the 
experiments. The effective concentration of the antagonists were chosen according to 
previous published studies. The number of observations is shown by ‘n’, which 
represents the number of animals used. 
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2.4. Analysis of results 
Changes in g tension were expressed as either a percentage of the maximal 
response to KCl (0.12 M) or the mean of the absolute values. The apparent pA2 values 
for antagonists were calculated from the Furchgott (1972) equation: pA2 = log (CR-1)-
log [B], where CR is the concentration ratio of agonist used in the presence and 
absence of antagonist, and B represents the concentration of antagonist, and is 
expressed as pA2 + S.E.M. The significance of differences between the control and 
the test responses was determined using analysis of variance (ANOVA) which was 
followed by Bonfferroni-Dunnett’s t-test, where P values less than 0.05 were taken as 
significant. The data and statistical analysis comply with the recommendations on 
experimental design and analysis in pharmacology (Curtise et al., 2015). 
 
2.5.Experimental design: Emesis testing 
All experimental procedures were in compliance with the US Animals (Scientific 
Procedures) Act 1986, and were carried out using age-matched animals of either sex 
(female 36.5+1.2 g; adult male 71.1+1.2 g).   
Ten experimentally naive male shrews were tested to determine SB-242084 is 
anti-emetic. Intially, shrews were injected with vehicle (saline with 8% hydroxy-
propyl-B-cyclodextrin and 25 mmol/l citric acid (Jones et al., 2002); n=5) or SB-
242084 (1 mg/kg/2 ml, ip; n=5) 40 min prior to exposure to provocative motion (10 
min, 1 Hz, 4 cm lateral displacement). After the administration of a drug or vehicle, 
each animal was placed individually in a transparent cage (100 W x 150 L x 150 H 
mm)  and observed for any behavioural change. After a described time, a horizontal 
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motion stimulus of 1 Hz and a 40 mm lateral displacement of the shaker platform was 
commenced for 10 min.  
Previous experiments showed that these parameters were suitable to induce a 
reliable and reproducible emetic response ((Javid and Naylor 1999, Chan et al., 2007; 
Tu et al., 2017). Animals were observed for emesis during motion exposure and for 
20 min after exposure. Emesis (with and without vomiting) was recorded to computer 
by an observer using software (JWatcher). Twelve days after testing with motion 
animals were divided into two groups (n=5 per group), receiving vehicle or SB-
242084 injections 40 min prior to intragastric delivery of CuSO4 (120 mg/kg/5 ml, 
gavage). To control for potential carryover effects, those animals receiving the vehicle 
during the motion testing (n=5) were assigned to receive SB-242084 for CuSO4 
testing. This was conducted to determine if the observed effects carried over from one 
experimental condition to the next.  Animals were observed for 30 min post-treatment 
for the occurrence of emesis. In all experiments, the number of emetic episodes 
(defined as productive vomiting or as dry retching) and the latency of onset to the first 
emetic episode were recorded.  It should be noted that the animals were kept and 
tested in exactly the same environment to obviate confounding differences of 
olfactory, visual and other cues.  All the experiments were conducted at the same time 
every day.   
 
2.6. Drugs 
5-Hydroxytryptamine maleate (Sigma), 8-OH-DPAT (8-hydroxy-2(di-n-dipropyl-
2-aminotetralin hydrobromide) (BRI), DOI(+)-1-(2,5-dimethoxy-4-iodophenyl)-2-
amino-propane (Sigma), WAY100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl] 
ethyl]- N- (2-pyridinyl) cyclohexanecarboxamidetrihydrochloride) (Research 
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Biochemicals Inc), SB269970 (®)-3-(2-(2-(4-Methyl-piperidin-1-yl)ethyl)-pyrolidine-
1-sulphonyl)-phenol)  and SB258585 (4-Iodo-N-[4-methoxy-3-(4-methyl-piperazin-1-
yl)-phenyl]-benzenesulphonamide) (Glaxosmithkline), MDL-100907 (®-(+)-alpha-
(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol) (Vernalis), 
RS-127445 (2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine) (Vernalis), SB-
242084 (6-chloro-5-methyl-1-[2-(2-methylpyridyl-3-oxy)-pyrid-5-yl carbamoyl] 
(Vernalis), hydroxy-propyl-B-cyclodextrin and citric acid (Sigma),CuSO4 (Sigma). 
All drugs were dissolved in distilled water except for SB-242084, RS-127445 and 
MDL-100907 which were dissolved in 50% DMSO at 1 mM concentration with 
distilled water being used for further dilutions. Preliminary experiments established 
that the vehicles used  did not show any effect on the tissues. 
 
3.0. Results 
3.1. The ability of 5-HT receptor antagonists to modify 5-HT induced contractions 
The non-cumulative addition of 5-HT (10.0 nM-30.0 µM) induced 
concentration-dependent contraction response curves in all segments examined. 
In   tissues taken  from the proximal region but not the central region of  the 
intestinal tract, pre-treatment with WAY-100635 (1.0 µM) significantly (P<0.05) 
reduced the contractions induced by concentrations of 5-HT lower than 0.1 µM 
(Figure 1). The concentration response curves to 5-HT were shifted to the right with 
the maximum responses being comparable to the control values. Estimated pA2 value 
for WAY-100635 to antagonise the effects of 5-HT was 6.5+0.1 in the proximal 
region. In contrast, in the terminal segments the contraction responses to 5-HT at 
concentrations higher than 30.0 nM were significantly (P<0.01) greater than  those in 
control tissues  (Fig. 1). 
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MDL-100907 (1.0 µM) induced a rightward shift of the concentration 
response curve to 5-HT without affecting the maximum response in segments taken 
from the terminal but not the proximal and central regions of the intestine (Fig. 2).  
An estimated pA2 value for  MDL-100907  to antagonise the effects of 5-HT was 
7.3+0.4. 
RS-127445 (1.0 µM), in tissues taken from the central and terminal regions of 
the intestine, attenuated the  contraction responses to 5-HT (30 nM to 1.0 µM in the 
central region and 3.0 nM to 0.3 µM in the terminal region) significantly (P<0.05, 
0.01) without reducing the maximal response (Fig. 3). Estimated pA2 values for RS-
127445  to antagonise the effects of 5-HT were 7.4+0.6 and 7.2+0.4 in tissues taken 
respectively from the central and terminal regions of the intestine. RS-127445 (1.0 
µM), failed to modify the effects of 5-HT  in the proximal region. 
SB-242084 (1.0 µM), attenuated the contraction responses to 5-HT in the  
concentration range of 10.0 nM to 100/300 nM significantly (P<0.05, 0.01) in tissues 
taken from the proximal and central (but not consistently in the terminal) regions of 
the intestine without significantly reducing the maximum response (Fig. 4). Estimated 
pA2 values for SB-242084 to antagonise the effects of 5-HT were 7.1+0.6 and 7.8+0.4 
in tissues taken from the proximal and central regions of the intestine. 
The application of SB258585 (1.0 µM) and SB269970A (1.0 µM) failed to modify 5-
HT-induced contractions in any tissue examined (data not shown).  
 
3.2. Effect of 8-OHDPAT in the absence and presence of 5-HT1A and 5-HT7 
receptor antagonists  
The non-cumulative addition of 8-OH-DPAT (10.0 nM- 30.0 µM) failed to 
induce a contraction or relaxation response in any tissues under basal tension. 
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However, when tissues were pre-contracted  with KCl  (0.12 M), 8-OH-DPAT at 
concentration range of 3.0- 30.0 µM induced a relaxation response in all regions of 
the intestine. The application of WAY-100635 (1.0 µM) or SB269970A (1.0 µM) 
failed to modify the relaxation response to 8-OH-DPAT in all regions examined (data 
not shown).  
 
3.3. The ability of the 5-HT receptor antagonists to modify DOI- induced 
contractions 
The application of DOI at concentrations of 10.0 nM to 300.0 nM induced a 
concentration-dependent contraction. The contraction responses achieved in the 
terminal regions of the intestine were smaller compared to those achieved in the 
proximal and central regions (Fig. 5-9). However, at concentrations of 1.0 µM and 
higher the contraction responses decreased, revealing a bell-shaped concentration 
response curve in all regions of the intestine (Fig. 5-8).  
The application of WAY-100635 (1.0 µM) failed to modify the DOI-induced 
contraction responses up to 0.3 µM in all tissues examined. However, the higher 
concentrations of  DOI (<10.0 µM) induced significantly (P<0.05) greater contraction 
responses in tissues taken from the proximal  and terminal but not the central region 
of the intestine. At a concentration of 10.0 µM or higher the responses were 
comparable to those in control tissues (Fig.  5). In the presence of  MDL-100907 (1.0 
µM)  the contraction responses to DOI at concentrations higher than 1.0 µM were 
significantly (P<0.05) greater as compared to the control values in all tissues 
examined (Fig. 6). MDL-100907 failed to modify the contractions induced by the 
lower concentrations of DOI (<1.0 µM). 
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RS-127445 (1.0 µM)  significantly (P<0.05, 0.01) reduced the contraction 
responses to lower concentrations of DOI  (>1.0 nM –1.0 µM)  in segments taken 
from the central and terminal but not from the proximal region of the intestine (Fig. 7), 
but increased the contractions to higher concentrations of DOI  (10.0-30.0 µM)  (Fig. 
7). 
SB242084  (1.0 µM)  significantly (P<0.05, 0.01) antagonized the contraction 
responses to lower concentrations of DOI (0.1-0.3 µM) in the central region, and 
(30.0 nM- 0.1  µM) in the terminal region, but not in the proximal region (Fig. 8). 
SB242084 enhanced the contractions to the higher concentrations of  DOI and is 
achieved significance (P<0.05, 0.001) mainly in the central and terminal regions of 
the intestine (Fig. 8). 
 
3.4. Effect of SB-242084 on emesis 
SB-242084 had no statistically significant effects on the total number of emetic 
episodes to motion exposure (Cox regression, P<0.05; Fig. 9); however, this agent did 
produce signficantly longer lantency to the first emetic episode (Fig. 9). In contrast to 
motion testing, SB-242084 pre-treatment resulted in a statistically significant decrease 
in total number of emetic episodes produced by intragastric CuSO4 (t-test, P<0.05; 
Fig. 10).  
 
4.0 Discussion 
The present study investigated the involvement of 5-HT1A , 5-HT2A , 5-HT2B , 5-
HT2C  receptors in mediating responses to 5-HT, DOI, and 8-OH-DPAT. The non-
cumulative addition of 5-HT induced concentration related contraction responses in 
all segments of the intestine, and relaxation responses were not observed. WAY-
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100635 is a potent and selective 5-HT1A receptor antagonist with an IC50 of 1.35 nM 
in the rat hippocampus and over 100-fold selectivity for the 5-HT1A receptors over 
other receptors (Fletcher et al., 1996). The antagonism afforded by WAY-100635 
indicates the involvement of 5-HT1A receptors in the contraction induced by 
nanomolar concentrations of 5-HT in the proximal region of the intestine. This profile 
of action was not seen in the central region of the intestine as the responses were 
comparable to those in control tissues. However, this profile of action  was quite 
different in segments taken from the terminal region of the intestine since WAY-
100635  facilitated a greater contraction response to 5-HT. The present results suggest 
both a regional difference within the intestine of Suncus murinus  in terms of a 5-
HT1A receptor involvement in mediating the responses to 5-HT and in the nature of 
the response- contraction versus relaxation.   
Classical subtypes of 5-HT receptor that have been identified in the gut include 5-
HT1A receptors which are present in enteric nerves and ganglia (Kirchgessner et al., 
1993). 5-HT1A receptors function to presynaptically inhibit the release of 
acetylcholine at nicotinic synapses and the secretion of tachykinins (Broad et al., 
1993), and postsynaptically to hyperpolarize enteric neurones (Galligan and North, 
1991; Galligan et al., 1988; Pan and Galligan, 1994).  If 5-HT1A receptors are 
involved in mediating relaxation or inhibitory responses in the intestine of Suncus 
murinus,  it is a complex mechanism because the application of WAY-100635  
revealed a greater contraction response to 5-HT in the terminal region of the intestine. 
Whether this effect involves a different action on post- or presynaptic receptors in the 
different regions of the intestine remains to be established. 
In the present study, and in line with previous experiments, the non-cumulative 
addition of DOI revealed a bell-shaped response; a contraction developing at low 
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concentrations (first phase) (10.0 nM - 0.1 µM),  followed by a decreasing contraction 
(second phase) (1.0 – 10.0 µM ). It has been shown that DOI has  agonistic activity at 
5-HT2 receptors with pEC50 values of 7.3, 7.4 and 7.8 for  the 5-HT2A, 5-HT2B and 5-
HT2C receptors, respectively (Baxter et al. 1995). DOI also has  low affinity (6,938 
nM) for the 5-HT1A receptors  (Zifa and Fillion, 1992).  
The ability of WAY 100635 to induce a greater contraction response to DOI in the 
declining contraction phase, in the proximal and terminal segments but not in the 
central region of the intestine, suggests the involvement of  5-HT1A receptors in 
mediating the second phase of DOI. Although DOI has a relatively low affinity for the 
5-HT1A as compared to the 5-HT2 receptors (see above), with increasing concentration 
this may become significant. Stimulation of the 5-HT1A receptors located on 
cholinergic nerves in the gut may reduce acetylcholine release (Kirchgessner et al., 
1993).  However, our further experiments using atropine revealed no involvement of 
the cholinergic component in mediating a response to DOI (unpublished data).  
In previous experiments it has been shown that 5-HT2 receptors play an important 
role in mediating a contraction response to 5-HT and DOI (Javid and Naylor, 1999b). 
In the present study, attempts were made to investigate further the  5-HT2 receptor 
subtypes using more selective and specific antagonists. MDL 100907 has nanomolar 
affinity (Ki= 0.85 nM, as an average value) for 5-HT2A receptors in various assays 
and shows >100 fold separation from all other receptors measured (Kehne et al., 
1996). In the present investigation, the ability of MDL 100907 to induce a greater 
contraction response to micromolar concentrations but not lower concentrations of 
DOI suggests the involvement of 5-HT2A receptors in the declining contraction 
response in all intestinal regions. Therefore, this suggests that the contraction 
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responses achieved at lower concentrations of DOI could be either 5-HT2B or 5-HT2C 
receptor mediated.  
To test this hypothesis further, experiments using selective  5-HT2B or 5-HT2C 
receptor antagonists were conducted. Pre-treatment with the 5-HT2B and 5-HT2C 
receptor antagonists, RS-127445 (Bonhaus et al., 1999) and SB242084 (Kennett et al., 
1997) respectively antagonized the contractions induced by DOI at concentrations 
lower than 1.0  µM, in segments taken from the central and terminal regions of 
intestine, whilst inducing a greater contraction response to higher concentrations of 
DOI in all regions of the intestine. RS-127445  has been shown to have nanomolar 
affinity for the 5-HT2B receptors (pKi= 9.5 + 0.1) and 1000-fold selectivity for this 
receptor as compared to other receptors and ion channel binding sites (Bonhaus et al., 
1999).  On the other hand, SB242084 has high affinity (pKi= 9.0) for the cloned 
human 5-HT2C receptor and 100 to 158-fold selectivity over the closely related cloned 
human 5-HT2B and 5-HT2A receptors, respectively. It also has over 100-fold 
selectivity over a range of other 5-HT, dopamine, and adrenergic receptors (Kennett et 
al., 1997). There is some discrepancy between the antagonist apparent pA2 values in 
this study and their corresponding binding affinity values in other studies (Kehne et 
al., 1996; Bonhaus et al., 1999; Kennett, 1997). However, this could be due to species 
differences and also the fact that brain tissues or cell lines were used in other studies 
to estimate the affinity of antagonists. 
Several studies have shown that 5-HT2A and 5-HT2C receptor antagonism may 
lead to opposite functional effects (Fletcher et al., 2002; Eberle-Wang et al., 1996; 
Meltzer et al, 1989a, 1989b; Reavill et al., 1999). For example, cocaine-induced 
locomotor activity was attenuated by the antagonism of 5-HT2A receptors, whilst 
potentiated  by a  5-HT2C receptor antagonist (Fletcher et al., 2002). In other 
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experiments, orofacial dyskinesias, a severe side effect associated with the prolonged 
use of anti-psychotic drugs, which is also present in a number of hyperkinetic 
disorders of the basal ganglia in humans, has been attenuated by 5-HT2C receptor 
antagonism in rats (Eberle-Wang et al., 1996). More recent studies by Creed-Carson 
et al (2011), suggested that the antagonism of 5-HT2C receptors could be targeted for 
the development of new anti-psychotic drugs. In line with the above studies, the 
present studies indicated a differential effects to the application of DOI when the 
central and terminal regions of the intestine were antagonized by  the 5-HT2A receptor 
antagonist as compared to the antagonism afforded by the 5-HT2C receptor antagonist 
in  the same regions of the intestine. Additionally, the 5-HT2B receptor antagonist 
induced the same profile of action on the responses to DOI as the 5-HT2C receptor 
antagonist. Furthermore, an opposite profile of action was observed when  the 
contractile responses to 5-HT in the central region of the intestine were antagonized 
by the  5-HT2A receptor antagonist as compared with the antagonism by 5-HT2B or 5-
HT2C receptor antagonists.  These observations provide evidence for the Suncus 
murinus intestine as a useful model for characterizing the action of novel therapeutics, 
including anti-psychotics. 
As an initial test of novel therapeutics, we investigated the action of the selective 
5-HT2C receptor antagonist SB-242084 on emesis. SB-242084 had inhibitory effects 
on emesis provoked by motion exposure and intragastric CuSO4. We used a broad set 
of stimuli to activate three peripheral emetic inputs, including the action of 
provocative motion on the vestibular system and intragastric CuSO4 on vagal and area 
postrema pathways (Horn et al., 2014). Our experiments suggest a broad therapeutic 
action of 5-HT2C receptors on emesis. Further experiments, including SB-242084, and 
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other 5-HT agents, should be conducted to establish the site of functional effects on 
emesis and other therapeutic modalities.  
In summary, the present data strongly suggests different effects for 5-HT2B and 5-
HT2C receptor activation in Suncus murinus intestine: a contraction response to lower 
concentrations of DOI and probably an inhibitory response to higher concentrations of 
DOI. The results provide evidence for a potential role for 5-HT2C receptors in the 
intestine to moderate contraction responses. The present study also indicates regional 
differences for the involvement of 5-HT receptors in inducing such effects. Activation 
of 5-HT1A receptors may attenuate or potentiate  the responses to 5-HT depending on 
the region of the intestine studied. Indeed the 5-HT1A and 5-HT2 receptors are 
involved in mediating diarrhoea in IBD patients (Chen et al., 2001; Kadowaki et al., 
1996; Margo et al., 2002). Thus Suncus murinus intestine would provide a good 
model to substantiate the role of 5-HT receptor subtypes in designing novel 
therapeutics. 
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Fig. 1. The contractile response to 5-HT (10 nM- 30 uM) in the absence and presence of 
WAY-100635 (1uM) in  segments taken from the proximal (1-3 cm distal to the pyloric 
sphincter) , central  (6-7 cm distal to the pyloric sphincter), and terminal (1-3 cm 
proximal to the anal region) regions of the Suncus murinus intestine. Each point 
represents the mean+ S.E.M.; n=6. * P<0.05, ** P<0.01 compared to the 5-HT control 
values. 
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Fig. 2. The contraction response to 5-HT (1 nM-30 uM) in the absence and presence 
of 5-HT2A receptor antagonist, MDL 100907 (1uM), in the segments taken from the 
proximal (1-3 cm distal to the pyloric sphincter) , central  (6-7 cm distal to the pyloric 
sphincter), and terminal (1-3 cm proximal to the anal region) region of the Suncus 
murinus intestine. Each point represents the mean+ S.E.M.; n=4. * P<0.05  compared 
to the control values. 
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Fig. 3. The contraction response to 5-HT (1 nM-30 uM) in the absence and presence 
of 5-HT2B receptor antagonist, RS-127445 (1uM), in the segments taken from the 
proximal (1-3 cm distal to the pyloric sphincter) , central  (6-7 cm distal to the pyloric 
sphincter), and terminal (1-3 cm proximal to the anal region) region of the Suncus 
murinus intestine. Each point represents the mean+ S.E.M.; n=4. * P<0.05 and  ** 
P<0.01  compared to the control values. 
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Fig. 4. The contraction response to 5-HT (1 nM-30 uM) in the absence and presence 
of 5-HT2C receptor antagonist, SB242084 (1uM), in the segments taken from the 
proximal (1-3 cm distal to the pyloric sphincter) , central  (6-7 cm distal to the pyloric 
sphincter), and terminal (1-3 cm proximal to the anal region) region of the Suncus 
murinus intestine. Each point represents the mean+ S.E.M.; n=4. * P<0.05 and  ** 
P<0.01  compared to the control values. 
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Fig. 5. Representative data showing the contractile response to DOI (10 nM- 30 uM) 
in the absence and presence of WAY-100635 (1uM) in the segments taken from 
proximal and terminal region of the Suncus murinus intestine. Each point represents 
the mean+ S.E.M.; n=6. * P<0.05 compared to the DOI control values. 
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Fig. 6. The contraction response to DOI (3 nM-30 uM) in the absence and presence of 
5-HT2B receptor antagonist, MDL 100907 (1uM), in the segments taken from the 
proximal (1-3 cm distal to the pyloric sphincter) , central  (6-7 cm distal to the pyloric 
sphincter), and terminal (1-3 cm proximal to the anal region) region of the Suncus 
murinus intestine. Each point represents the mean + S.E.M.; n=5. * P<0.05, ** 
P<0.01 and *** P<0.001 compared to the control values. 
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Fig. 7. The contraction response to DOI (3 nM-30 uM) in the absence and presence of 
5-HT2B receptor antagonist, RS-127445 (1uM), in the segments taken from the 
proximal (1-4 cm distal to the pyloric sphincter) , central  (6-7 cm distal to the pyloric 
sphincter), and terminal (1-3 cm proximal to the anal region) region of the Suncus 
murinus intestine. Each point represents the mean+ S.E.M.; n=5. * P<0.05, ** P<0.01 
and *** P<0.001 compared to the control values. 
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Fig. 8. The contraction response to DOI (3 nM-30 uM) in the absence and presence of 
5-HT2C receptor antagonist, SB242084 (1uM), in the segments taken from the 
proximal (1-3 cm distal to the pyloric sphincter) , central  (6-7 cm distal to the pyloric 
sphincter), and terminal (1-3 cm proximal to the anal region) region of the Suncus 
murinus intestine. Each point represents the mean+ S.E.M; n=5. * P<0.05 and ** 
P<0.01 compared to the control values. 
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Fig. 9. Effect of pre-treatment with vehicle or SB242084 (1 mg/kg) on motion-
induced emesis (10 min, 1 Hz). Top for panel show the total number of emetic 
episodes, duration of emesis (from the 1st to the last episode), episodes with vomiting, 
and episodes without vomiting. Data represent the mean + S.E.M.; n=5. Bottom plot 
shows the cummulative latency to the first emetic episode. * P<0.05, Cox regression.  
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Fig. 10. Effect of pre-treatment with vehicle or SB242084 (1 mg/kg) on intragastric 
CuSO4-induced emesis (120 mg/kg, gavage). Top for panel show the total number of 
emetic episodes, duration of emesis (from the 1st to the last episode), episodes with 
vomiting, and episodes without vomiting. Data represent the mean + S.E.M.; n=5. * 
P<0.05, t-test. Bottom plot shows the cummulative latency to the first emetic episode.  
 
 
 
 
 
